Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
A phase 1/2 trial of NUV-1511 in prostate cancer, pancreatic ductal adenocarcinoma and ovarian cancer, run by Nuvation Bio Inc., active and no longer recruiting.
Overview
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06334432 by Nuvation Bio Inc., with 466 participants enrolled, started 2024-03-14 and due to reach its primary completion in 2027-03. Interventions recorded: NUV-1511.
Similar pages
not linked directly; found by shared links- TrialA Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
- TrialA Study of DM002 in Patients With Advanced Solid Tumors
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
- TrialEarly Phase Study of KESONOTIDE™in Participants With Solid Tumours
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
- TrialA Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene
Shares Nuvation Bio and the tag pipeline.
- TrialStudy of ACE-86225106 to Treat Patients With Advanced Solid Tumors
Shares Ovarian cancer, Prostate cancer and the tag pipeline.
- TrialPhase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
- TrialStudy of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialA Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Shares Ovarian cancer, Prostate cancer and the tag pipeline.